About this document

HBIO Q4 2012 Financial Results Summary by paolomcpaki is a document available to read on EtoBox.

- Harvard Bioscience reported financial results for Q4 2012 and full year 2012, with Q4 revenues of $28.2 million, down 2.7% year-over-year but within guidance range. For the full year, revenues increased 2.1% to $111.2 million. - Net income declined for both periods due to increased spending on the developmental Regenerative Medicine Device (RMD) business, with the RMD business losses increasing for both Q4 and the full year. - The CEO commented that while focus was on the RMD business, actions were taken

Author

paolomcpaki

Language

EN